Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Doxycycline (Oracea) Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

NCT01469585
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
Doxycycline
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 1, 2026, 1:49 AM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Rituximab combined with Omalizumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

NCT02564471
View directory record Official record
Conditions
Rabies
Interventions
Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine
Drug · Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Not applicable Interventional

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

NCT02829060
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions
Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 1, 2026, 1:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Doxycycline in Cutaneous Schwannoma (NF2)

NCT05521048
View directory record Official record
Conditions
Neurofibromatosis Type 2
Interventions
Doxycycline Injection [Doxy]
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
doxycycline, placebo gel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

NCT02456662
View directory record Official record
Conditions
Drug-induced Nausea and Vomiting
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 2 Interventional

Treating Periodontal Infection: Effects on Glycemic

NCT00016835
View directory record Official record
Conditions
Periodontal Disease, Diabetes Mellitus, Type 2
Interventions
Supra-gingival scaling and placebo, Subgingival scaling and metronidazole, Subgingival scaling and doxycycline
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 1, 2026, 1:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

NCT07544251
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline, Doxycycline
Drug
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 1, 2026, 1:49 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease

NCT00355459
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Tetracycline: Doxycycline analog
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 1, 2026, 1:49 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

NCT04850313
View directory record Official record
Conditions
Bacterial Corneal Ulcer
Interventions
ProProKera Plus®
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 1, 2026, 1:49 AM EDT
Withdrawn Phase 4 Interventional

Doxycycline Outcomes in Lupus Erythematosus

NCT01014260
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Doxycycline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 1, 2026, 1:49 AM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Characterization of Doxycycline Pharmacokinetics and Adherence

NCT07755618
View directory record Official record
Conditions
Sexually Transmitted Infection
Interventions
Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group, Multi-Dose PK Phase - Intermittent Group
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 2Phase 3 Interventional

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

NCT01782989
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

Doxycycline and OA Progression

NCT00000403
View directory record Official record
Conditions
Osteoarthritis
Interventions
Doxycycline
Drug
Lead sponsor
Indiana University
Other
Eligibility
45 Years to 64 Years · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
6
States / cities
Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

NCT02207556
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
Doxycycline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 1, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

NCT01935622
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Interventions
Doxycycline, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 1, 2026, 1:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens

NCT00177333
View directory record Official record
Conditions
Abortion, Induced, Vomiting
Interventions
Doxycycline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 1, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Doxycycline monohydrate
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 1, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

NCT01160640
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 1, 2026, 1:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Doxycycline, Temozolomide and Ipilimumab in Melanoma

NCT01590082
View directory record Official record
Conditions
Melanoma
Interventions
Doxycycline, Ipilimumab, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 1, 2026, 1:49 AM EDT